Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV001090321 | SCV001245801 | pathogenic | not provided | 2018-07-01 | criteria provided, single submitter | clinical testing | |
Institute of Medical Genetics and Applied Genomics, |
RCV001090321 | SCV001480087 | pathogenic | not provided | 2021-02-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001090321 | SCV001545985 | uncertain significance | not provided | 2020-02-15 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant disrupts the p.Val235 amino acid residue in BEST1. Other variant(s) that disrupt this residue have been observed in individuals with BEST1-related conditions (PMID: 9700209), which suggests that this may be a clinically significant amino acid residue. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This missense change has been observed in individual(s) with Best vitelliform macular dystrophy (PMID: 11241846). This variant is not present in population databases (ExAC no frequency). This sequence change replaces valine with leucine at codon 235 of the BEST1 protein (p.Val235Leu). The valine residue is highly conserved and there is a small physicochemical difference between valine and leucine. |